Tobacco Cessation Support Lacking in Mental Health Facilities

Share this content:
Tobacco Cessation Support Lacking in Mental Health Facilities
Tobacco Cessation Support Lacking in Mental Health Facilities

FRIDAY, May 11, 2018 (HealthDay News) -- Many patients in mental health and substance abuse treatment facilities are not screened for tobacco use or offered treatments to facilitate tobacco cessation, according to research published in the May 11 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.

Kristy Marynak, M.P.P., from the CDC in Atlanta, and colleagues analyzed data from the 2016 National Mental Health Services Survey and the 2016 National Survey of Substance Abuse Treatment Services to examine tobacco-related policies and practices in mental health and substance abuse treatment facilities.

The researchers found that 48.9 percent of mental health treatment facilities reported screening patients for tobacco use in 2016; 37.6, 25.2, and 21.5 percent offered tobacco cessation counseling, nicotine replacement therapy, and non-nicotine tobacco cessation medications, respectively; 48.6 percent prohibited smoking in all indoor and outdoor locations. Overall, 64.0 percent of substance abuse treatment facilities reported screening patients for tobacco use in 2016; 47.4, 26.2, and 20.3 percent offered tobacco cessation counseling, nicotine replacement therapy, and non-nicotine tobacco cessation medications, respectively; 34.5 percent had smoke-free campuses.

"Full integration of tobacco cessation interventions into behavioral health treatment, coupled with implementation of tobacco-free campus policies in behavioral health treatment settings, could decrease tobacco use and tobacco-related disease and could improve behavioral health outcomes among persons with mental and substance use disorders," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths